Biomerica Inc (BMRA)

Form 8-K - Current report

Biomerica Lands a $1.75 Million CDMO Master Services Agreement for IVD Diagnostic Development

IRVINE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a developer and manufacturer...

Biomerica’s inFoods® IBS Data Accepted for Presentation at Digestive Disease Week 2026

IRVINE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global biomedical...

Biomerica Announces Medicare Administrative Contractor Confirmation of Individual Claim Review for inFoods® IBS, Opening a Scalable Medicare Commercialization Pathway

The Medicare Administrative Contractor (MAC) responsible for processing inFoods® IBS claims has confirmed to...

Biomerica Launches inFoods® IBS in Canada Through Partnerships with Phoenix Airmid Biomedical and CanAlt Health Labs

— Represents Biomerica’s First Commercial Entry into the Canadian Market for its Precision, Diagnostic-Guided...

Biomerica Reports Third Quarter Fiscal 2026 Financial Results

IRVINE, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (“Biomerica” or the...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Biomerica Receives First Commercial Order for its H. pylori test (Hp Detect™) from One of the Largest Clinical Laboratory Chains in Europe

First Commercial Order by Large Lab Chain: Biomerica has received its first commercial order for Hp Detect™...

Biomerica Receives MHRA Registration for hp+detect™, Allowing Commercial Sales in Great Britain

UK Market Entry: MHRA registration authorizes hp+detect™ for commercial sale in Great BritainActive...

Form S-8 - Securities to be offered to employees in employee benefit plans

Biomerica Reports Real-World Data: Nearly 60% of IBS Patients Achieved Clinically Meaningful Pain Reduction and 68% Achieved Bloating Reduction with the inFoods® IBS Therapy

Key Highlights Responder Analysis: 59.4% of patients achieved ≥30% reduction in abdominal pain; 68.1% achieved...

Vietnam Approves Biomerica’s EZ Detect™ for Nationwide Distribution

Approval Marks Biomerica’s Strategic Entry into Southeast Asia’s Rapidly Growing Healthcare MarketSimple...

Form 4 - Statement of changes in beneficial ownership of securities

Biomerica Reports Second Quarter Fiscal 2026 Financial Results

Operating Expenses Decline 4% Year-to-DateBalance Sheet Strengthens and Working Capital Improves by 14.7...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]